Neuro-Oncology
Reviews


Volume 20 Number 4
April 2018


Home > Publications > Neuro-Oncology Reviews > Volume 20, Year 2018 > Number 4, April






Vanderbeek AM, Rahman R, Fell G, Ventz S, Chen T, Redd R, Parmigiani G, Cloughesy TF, Wen PY, Trippa L, Alexander BM.
The clinical trials landscape for glioblastoma: is it adequate to develop new treatments?
Neuro Oncol. 2018 Apr 5, 2018;20(8):1034-1043. doi: 10.1093/neuonc/noy027. PMID: 29518210. Meta-analysis.




Lu VM, Jue TR, McDonald KL, Rovin RA.
The survival effect of repeat surgery at glioblastoma recurrence and its trend: A systematic review and meta-analysis.
World Neurosurg. 2018 Apr 11. pii: S1878-8750(18)30732-0. doi: 10.1016/j.wneu.2018.04.016. Source | Abstract | Similar articles






Nandu H, Wen PY, Huang RY.
Imaging in neuro-oncology.
Ther Adv Neurol Disord. 2018 Feb 28;11:1756286418759865. doi: 10.1177/1756286418759865. eCollection 2018.
Source . Similar articles





Levin VA, Ellingson BM.
Understanding Brain Penetrance of Anticancer Drugs.
Neuro Oncol. 2018 Feb 21. doi: 10.1093/neuonc/noy018. [Epub ahead of print]
Source . Similar articles




Thust SC, Heiland S, Falini A, Jäger HR, Waldman AD, Sundgren PC, Godi C, Katsaros VK, Ramos A, Bargallo N, Vernooij MW, Yousry T, Bendszus M, Smits M.
Glioma imaging in Europe: A survey of 220 centres and recommendations for best clinical practice.
Eur Radiol. 2018 Mar 13. doi: 10.1007/s00330-018-5314-5. [Epub ahead of print]
Source . Similar articles






Mandonnet E, Duffau H.
An attempt to conceptualize the individual onco-functional balance: Why a standardized treatment is an illusion for diffuse low-grade glioma patients.
Crit Rev Oncol Hematol. 2018 Feb;122:83-91. doi: 10.1016/j.critrevonc.2017.12.008. Epub 2017 Dec 13.
Source . Similar articles









Cai X, Sughrue ME.
Glioblastoma: new therapeutic strategies to address cellular and genomic complexity.
Oncotarget. 2017 Dec 20;9(10):9540-9554. doi: 10.18632/oncotarget.23476. eCollection 2018 Feb 6.
Source . Similar articles




Coleman N, Ameratunga M, Lopez J.
Development of Molecularly Targeted Agents and Immunotherapies in Glioblastoma: A Personalized Approach.
Clin Med Insights Oncol. 2018 Feb 26;12:1179554918759079. doi: 10.1177/1179554918759079. eCollection 2018.
Source . Similar articles




Jindal V.
Role of Chimeric Antigen Receptor T Cell Therapy in Glioblastoma Multiforme.
Mol Neurobiol. 2018 Mar 9. doi: 10.1007/s12035-018-0978-z. [Epub ahead of print]
Source . Similar articles




Prinzing BL, Gottschalk SM, Krenciute G.
CAR T-cell therapy for glioblastoma: ready for the next round of clinical testing?
Expert Rev Anticancer Ther. 2018 May;18(5):451-461. doi: 10.1080/14737140.2018.1451749. Epub 2018 Mar 16.
Source . Similar articles




Vanderbeek AM, Rahman R, Fell G, Ventz S, Chen T, Redd R, Parmigiani G, Cloughesy TF, Wen PY, Trippa L, Alexander BM.
The clinical trials landscape for glioblastoma: is it adequate to develop new treatments?
Neuro Oncol. 2018 Mar 6. doi: 10.1093/neuonc/noy027. [Epub ahead of print]
Source . Similar articles









Chastagner P.
Medulloblastoma: A turning point from fundamental advances to improved survival and decreased sequelae.
Neurochirurgie. 2018 Feb 12. pii: S0028-3770(17)30182-0. doi: 10.1016/j.neuchi.2017.10.006. [Epub ahead of print]
Source . Similar articles